Damora Therapeutics, Inc. DMRA
Regular-session close
After hours · Nov 20, 4:01 PM ET
- YTD
- +0.91%
- 1 year
- +33.83%
5D +0.19 (+0.83%)
- Market cap
- 1.44B
- EPS (ttm)
- 1.71
- Shares out
- 61.90M
- P/E ratio
- 13.58
- Forward P/E
- -10.63
- YTD return
- +0.91%
- 1-year return
- +33.83%
- 50-day average
- 21.79
- 200-day average
- 25.44
- Enterprise value
- 1.11B
- Volume
- 643.38K
- Avg volume
- 576.73K
- Open
- 23.81
- Previous close
- 24.30
- Day's range
- 23.13 – 24.51
- 52-week range
- 16.31 – 34.14
- Beta
- 1.51
- Analysts
- Strong Buy
- Price target
- 46.78 (+101.5%)
- Earnings date
- Mar 18, 2027
Key statistics
- Price / book
- 3.93
- Free cash flow
- -18.55M
- Total cash
- 528.48M
- Total debt
- 1.10M
- Return on equity
- -115.80%
- Short % of float
- 8.84%
Fundamental scorecard
5 of 25 checks passed on DMRA’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 40.00
- Target (mean)
- 46.78
- Target (high)
- 59.00
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 18, 2027
Expected Mar 18, 2027. Consensus EPS estimate -0.47.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 18, 2027 | Dec 30, 2026 | -0.56041 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.48251 | -0.40 | +0.08 | +17.10% |
| Aug 11, 2026 | Jun 30, 2026 | -0.41395 | -0.39 | +0.02 | +5.79% |
| May 12, 2026 | Mar 31, 2026 | -0.21 | -0.62 | -0.41 | -195.24% |
| Mar 18, 2026 | Dec 31, 2025 | -0.14 | -3.24 | -3.10 | -2,216.35% |
| Nov 6, 2025 | Sep 30, 2025 | -0.09681 | -2.36 | -2.26 | -2,337.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Guggenheim | main | Buy | Buy |
| Sep 29, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 25, 2026 | Guggenheim | main | Buy | Buy |
| Jul 30, 2026 | Wedbush | main | Outperform | Outperform |
| Jul 27, 2026 | Jefferies | init | — | Buy |
| Jul 21, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- damoratx.com
News
Damora Therapeutics, Inc. (DMRA) Presents at UBS Global Biopharma Conference 2026 Transcript
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Breaks Above 50 Day Moving Average After Analyst Downgrade Guggenheim Maintains Buy on Damora Therapeutics, Lowers Price Target to $59
Damora Therapeutics Q3 EPS $(0.40) Beats $(0.48) Estimate
Damora Therapeutics’ Preclinical Data Highlighting Potential Of DMR-001 Accepted For Poster Presentation At 2026 ASH Annual Meeting And Exposition
Your note
Sign in to keep a note on DMRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRUNO JULIANNE | Director | Conversion of Exercise of derivative security | Feb 8, 2026 | 137,032 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| FIRMANI LORI | Chief Financial Officer | Sale | Jan 1, 2026 | 931 |
| HEWES LEMUEL BECKER | Officer | Stock Award(Grant) | Jan 4, 2026 | 264,629 |
| JARRETT A JENNIFER | Chief Executive Officer | Purchase | Sep 24, 2026 | 512,500 |
| SATTARZADEH SHERWIN | Chief Operating Officer | Stock Award(Grant) | Jan 4, 2026 | 190,376 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.43% | 9,549,056 | 221.73M | Sep 29, 2026 |
| Fairmount Funds Management LLC | 14.07% | 8,713,000 | 202.32M | Sep 29, 2026 |
| Avoro Capital Advisors LLC | 6.11% | 3,783,000 | 87.84M | Sep 29, 2026 |
| Venrock Adviser, LLC | 5.82% | 3,603,595 | 83.68M | Sep 29, 2026 |
| Blackrock Inc. | 5.68% | 3,514,573 | 81.61M | Sep 29, 2026 |
| RA Capital Management, L.P. | 3.88% | 2,399,702 | 55.72M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.96% | 1,835,051 | 42.61M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.98% | 1,227,145 | 28.49M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.35% | 834,040 | 19.37M | Aug 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.17% | 723,719 | 16.80M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.94% | 584,529 | 13.57M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.87% | 540,246 | 12.54M | Sep 29, 2026 |
